Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose tigecycline for multidrug-resistant Gram-negative hospital-acquired pneumonia
ChiCTR1900025792Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tigecycline in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and Gram-negative bacterial infection (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: 28-day prognosis. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
tigecycline
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR1900025792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025792.